Ranbaxy: Ranbaxy Buyers' $485M Deal In Generics MDL Gets Initial Nod

Ranbaxy Pharmaceuticals drug purchasers nabbed initial approval of a $485 million global settlement struck in March over claims the drugmaker manipulated the U.S. Food and Drug Administration's generic-drug approval process to box out competitors.